Ontology highlight
ABSTRACT:
SUBMITTER: Joyner MJ
PROVIDER: S-EPMC7456238 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Joyner Michael J MJ Wright R Scott RS Fairweather DeLisa D Senefeld Jonathon W JW Bruno Katelyn A KA Klassen Stephen A SA Carter Rickey E RE Klompas Allan M AM Wiggins Chad C CC Shepherd John Ra JR Rea Robert F RF Whelan Emily R ER Clayburn Andrew J AJ Spiegel Matthew R MR Johnson Patrick W PW Lesser Elizabeth R ER Baker Sarah E SE Larson Kathryn F KF Ripoll Juan G JG Andersen Kylie J KJ Hodge David O DO Kunze Katie L KL Buras Matthew R MR Vogt Matthew Np MN Herasevich Vitaly V Dennis Joshua J JJ Regimbal Riley J RJ Bauer Philippe R PR Blair Janis E JE Van Buskirk Camille M CM Winters Jeffrey L JL Stubbs James R JR Paneth Nigel S NS Verdun Nicole C NC Marks Peter P Casadevall Arturo A
The Journal of clinical investigation 20200901 9
BACKGROUNDConvalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.METHODSThus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, wi ...[more]